Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy"

Am J Gastroenterol. 2021 Dec 1;116(12):2474. doi: 10.14309/ajg.0000000000001495.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • COVID-19*
  • Humans
  • Proton Pump Inhibitors* / adverse effects
  • Risk Factors
  • SARS-CoV-2

Substances

  • Proton Pump Inhibitors
  • Angiotensin-Converting Enzyme 2